SB Execs: More Pie, Please
SmithKline's middle managers aren't particularly happy with their financial stake in the new Glaxo SmithKline. Thanks to a new patent on clavulanic acid, SB's #2 drug which was supposed to lose patent protection in 2002, and the withdrawal of a key competitor to SB's new diabetes drug rosiglitazone, SB will probably be providing most of the near-term earnings growth to the combined company. But SB shareholders only get 41% of the combined company. SB employees will therefore be sharing the earnings of their company, reflected in the value of their options, disproportionately with Glaxo employees.
You may also be interested in...
New data seems to indicate an uptick in the percentage of premarket applications that receive a major deficiency letter. See what US FDA spokesperson Alison Hunt said about strategies to avoid them.
Japanese firm says it will end SHP647 development after trying unsuccessfully to find takers for GI drug similar to its blockbuster Entyvio, first flagged by European authorities over competition worries.
The Environmental Working Group and US PIRG suggest that beauty and personal-care firms should avoid using talc in loose powders, if not all cosmetic products, and that the US FDA should consider banning the ingredient due to the potential for asbestos contamination, among other concerns.